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Artificial lungAbstract Extracorporeal support (ECMO) is indicated in severe heart or lung failure with 80%
risk of mortality. In experienced centers, overall survival to discharge ranges from 40% in cardiac
arrest (ECPR) to 70% for respiratory failure in adults, 80% in children and newborns with pro-
longed ECMO support, severe lung injury can recover to normal function, re-defining irreversible
lung injury. In the future ECMO will be automatically controlled with care out of ICU or at home.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.ECLS (ECMO) has been standard care for newborn infants
and children with heart and lung disease since 1990, and for
adults with cardiac and respiratory failure since 2009 [1]. There
are currently over 70,000 cases in the ELSO Registry. 28,271 of
these cases are newborn infants with respiratory failure [2].
14,851 of these cases are patients managed with ECMO for
severe respiratory failure in the pediatric (6929) and adult
(7922) age groups [2]. The balance is cardiac support in chil-
dren and adults. The survival (hospital discharge) for adults
with severe respiratory failure in the last 5 years is 60%. The
indications for ECLS are 80% risk of mortality, measured
by appropriate parameters for each diagnosis and age group.
Since the first cases in the early 70s until 2005, ECMO circuits
were assembled on-site from a variety of devices. Despite the
variation in devices, the technology was relatively standard-
ized. Patients were deeply sedated, anticoagulated with heparin
titration, and regular efforts were made at lung recruitment(often resulting in barotrauma and pneumothorax). Bleeding
was the major complication. ECMO was often terminated on
day 14, 21, 30 because the lung failure appeared permanent
and irreversible. Transplantation was not an option. This era
is referred to as ECMO 1.
Major changes in the technology occurred in 2008 with
entire ECMO systems being developed by the Maquet, Sorin,
and Novalung companies in Europe [3–5]. The Maquet devices
were available in the United States in 2009. The new devices
resulted in much safer, simpler, prolonged management of
extracorporeal support and have led to a much wider use of
ECMO in respiratory failure. Prior to 2009 there were fewer
than 100 cases per year, and survival varied widely because
of the small numbers in each diagnostic group. With the new
devices there have been hundreds of cases each year and sur-
vival stabilized at about 60%. Improved devices have also
resulted in a change in patient management emphasizing min-
imal sedation, spontaneous breathing, and active physical ther-
apy. Bleeding is still the most common complication but is
manageable. Lung recovery occurs regularly after as much as
1 or 2 months of minimal or even no lung function [6,7]. Con-
sequently, ‘‘irreversible” lung failure is being re-defined. Bridg-
ing to lung transplantation is now a routine with ambulatory
ECMO [8]. We refer to this era as ECMO 2. Patient manage-
ment in ECMO 1 and ECMO 2 is demonstrated in Fig. 1.
Figure 1 Patient care during ECMO, 3 eras.
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mode of access. VA includes right atrial and systemic artery
cannulation, often done urgently during ECPR. Unique prob-
lems are perfusion to the distal leg when femoral artery access
is used: left atrial venting if there is no cardiac function, and
differential circulation if lung failure coincides with cardiac
failure treated by femoral perfusion. VA perfusion is short
(3–6 days) because the heart often recovers quickly, or not at
all (about 10–20%). When there is no heart recovery in a
day or two the patient should be converted to a VAD and con-
sidered for transplant. The overall survival from cardiac sup-
port is 30–50%. Many cases sustain irreversible brain injury
prior to ECMO.
ECMO for respiratory failure in adults and older children is
usually managed by venovenous (VV) access [9]. In VV access,
blood is drained from the right atrium or SVC and IVC, and
reinfused into the right atrium. This access puts the artificial
lung in series with the normal lungs rather than in parallel
(as in CPB or VA ECMO). The well-oxygenated infusion
blood mixes with the native venous return (which did not pass
through the ECMO circuit) so the resultant arterial PO2 and
saturation represents a mixture of the oxygenated extracorpo-
real blood and the unoxygenated venous blood which passes
through the nonfunctional native lungs. This desaturated arte-
rial blood combined with the normal cardiac output provides
more than adequate systemic oxygen delivery to support meta-
bolism, and the airway is managed at rest settings. With VV
access the patient is reliant on his or her own hemodynamics,
so cardiac output, pulmonary and systemic vascular resistance
are unchanged during extracorporeal gas exchange.
Selective CO2 removal
Membrane lungs are much more efficient at transferring CO2
than adding oxygen. This is because the inlet minus outlet dif-
ference for oxygen is limited to around 5 ccO2/dL, but inlet/
outlet difference for CO2 can be as high as 15–20 cc/dL. For
this reason a large amount of CO2 can be removed at much
lower blood flow than what is required for oxygenation. Selec-
tive CO2 removal in adults can be achieved with relatively low
extracorporeal flows (500–1000 cc/min). Gattinoni reported a
series of ARDS patients managed with extracorporeal CO2
removal (ECCOR) in 1986 [10]. The technique of selective
CO2 removal has been investigated many times since that orig-
inal publication. Selective CO2 removal is ideal for the man-
agement of status asthmaticus and for COPD in
exacerbation. It is currently being studied again for ARDS,with the intention of minimizing airway pressure and allowing
oxygenation by insufflation into the airway. Although devices
are being marketed specifically for CO2 removal, any infant or
pediatric system is fine for CO2 clearance in adults.Bridge to lung transplantation
In the past the requirement for ECMO was considered a con-
traindication to transplantation because the patients were in
severe primary respiratory failure and became wasted and frail
with the heavy sedation and paralysis. With the advent of
ECMO 2 bridge to transplantation has become routine prac-
tice [8]. In fact, a patient listed for transplantation who is
admitted for an exacerbation (formerly removed from the
transplant list) can now be managed with ECMO using double
lumen venovenous access, minimizing or eliminating sedation,
and encouraging ambulation, nutrition and physical therapy,
thus improving the status of the patient for subsequent trans-
plantation [11].ECMO in the next 10 years
Vascular access
VA access using the femoral vessels is the method of choice for
adults for cardiac support. VV access is preferred for respira-
tory failure. Currently, most venovenous access is achieved
with the use of a double lumen catheter, draining blood from
the vena cavae and right atrium and returning it to the right
atrium, aiming the return infusion toward the tricuspid valve
and right ventricle [12]. This approach will continue in the
future with variations of the method of placement, imaging
during placement, and new double lumen catheters. However
there will always be a need for two-catheter venovenous access,
draining from the femoral vessels and reinfusing into the right
atrium. This technique can be accomplished very quickly at the
bedside in an unstable patient, does not require radiographic
imaging, and is the most reliable way to quickly establish ven-
ovenous access. When access is established in emergency situ-
ations in this fashion the cannulation is changed after a day or
two to double lumen catheter via the jugular vein. This allows
removal of the femoral venous catheter and facilitates
ambulation.
The ECMO circuit
The next generation of ECLS pumps will emphasize automa-
tion and servo regulation, such that the desired extracorporeal
flow is set and the pump will automatically achieve that flow
despite a variety of conditions of the patient (coughing, activ-
ity, blood volume). In similar fashion, the arterial blood satu-
ration will be used to servo regulate the flow with calculations
comparing systemic oxygenation to extracorporeal flow and
mixed venous saturation built into the program so that the
desired arterial saturation will be reached automatically or, if
it cannot be reached, a proposed solution will be displayed.
Current membrane lungs are primarily square resulting in stag-
nation and thrombus formation in the corners. The next gen-
eration of devices will be round in all dimensions to
minimize stagnation and thrombosis. The blood flow required
Figure 2 Pulmonary artery to left atrium implantable membrane
lung.
Extracorporeal support 9for CO2 removal for adults can be between 500 and 1000 cc/
min with a high sweep flow. The sweep flow itself will be servo
regulated based on the exhaust gas CO2 so that adjustments of
the sweep flow will be automatic.
Anticoagulation
Current devices have nonthrombogenic coatings generally
based on heparin on the surface. This minimizes the need for
anticoagulation but does not eliminate it because the primary
cause of clotting on the artificial surfaces is platelet adhesion
and aggregation. The next generation of devices will have sur-
faces which inhibit platelet adhesion to the surface. Currently
this is being done with nitric oxide eluting from the plastic [13].
The use of nitric oxide or similar materials to prevent platelet
adhesion will greatly decrease the need for anticoagulation,
and when combined with surface antifibrin chemicals, may
eliminate the need for anticoagulation altogether. In the mean-
time, the anticoagulant of choice for ECLS may become direct
thrombin inhibitors such as argatroban and bivalirudin [14].
Heparin has always been used for ECLS but is dependent on
antithrombin for its activity and the response to heparin infu-
sion is affected by many variables in the blood. Direct throm-
bin inhibitors are simpler and act directly on thrombin
formation.
Patient management
With the automation and servo regulation in place, the pri-
mary person caring for the extracorporeal circuit and patient
will be the bedside ICU nurse. Some extra training will be
required, but the ECMO specialist will no longer need to be
sitting continuously at the bedside [15]. There will be a need
for ECMO specialists as the supervising team, educators,
and management of the circuit and emergencies. It will become
standard practice to have 10 or 20 patients on ECMO in any
given hospital at any given time, including the full spectrum
of ages and cardiac and respiratory support. For adult respira-
tory support management of ECMO in the ICU will be as rou-
tine as managing a patient on a ventilator or on renal
replacement therapy is today. While most adult patients are
on ECMO for 7–14 days, a significant fraction of patients will
be on ECMO for a month or more awaiting lung recovery or
perhaps transplantation. These patients are quite stable and
can be managed in stepdown units. The fact that there may
be several patients with respiratory failure on ECMO for a
month or more will result in the establishment of regional lung
failure centers which are equipped to manage a dozen or more
chronic ECMO patients at a time, bridging to transplantation
or to recovery. These units will be similar to the heart failure
centers now common practice in major medical centers.
ECMO patients will be managed in conventional hospital set-
tings or perhaps even at home with appropriate monitors and
alarms. This will be similar to the management of patients with
ventricular assist devices at home which has evolved over the
last 15 years.
Implantable (wearable) membrane lungs
Implantable membrane lungs are membrane devices attached
by conduits directly to the circulation, either to the heartdirectly or to peripheral vessels. The membrane lungs them-
selves will be paracorporeal, attached to the access cannulas
that pass through the skin. The reason for this is that the
devices will have to be changed from time to time and,
although they could be implanted subcutaneously or in the
pleural space, the need for evaluation and replacement makes
the paracorporeal position the most convenient for long term
support. These implantable lungs may be used for bridging
to transplantation and as destination therapy for end stage
lung disease in patients who are not candidates for transplan-
tation. Implantable membrane lungs can be used without the
need for blood pumps, relying either on pulmonary artery
pressure or systemic arterial pressure to drive blood through
the device. For patients who require oxygenation as well as
CO2 clearance and for patients who are in right ventricular
failure because of pulmonary hypertension, the implantable
lung will be placed from the pulmonary artery to the left
atrium [16] (Fig. 2). This allows essentially all of the circulation
to pass through the device depending on the relative resis-
tances of the pulmonary vascular bed and the device. With
high blood flows, full oxygenation and CO2 removal can be
achieved and the right ventricle is unloaded so the device also
acts as treatment for pulmonary hypertension with right ven-
tricular failure. PA to LA access was first used clinically in
2007 and has now been used in many patients primarily as a
bridge to transplantation in patients who are in right ventricu-
lar failure [17]. This access works very well but requires a tho-
racotomy for placement of the access cannulas and always
runs the risk of systemic embolization.
Devices attached to a major artery and vein, notable the
subclavian or axillary artery and vein can achieve blood
flows in the range of 20% of the cardiac output. This is suffi-
cient to remove all the metabolically produced CO2 and has
the advantage of avoiding systemic arterial embolization. AV
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will be used for end stage lung disease patients who are not
candidates for transplantation. As destination therapy these
devices will be used first for palliation of severe COPD.
Because the goal is primarily CO2 removal, the devices can
be small in size and have a relatively small gas exchange sur-
face area.
The application of the devices and techniques described
above will result in the next generation of ECMO manage-
ment, which we call ECMO 3 (Fig. 1). The characteristics of
ECMO 3 will be awake, extubated, spontaneously breathing
patients, without systemic anticoagulation, managed in step-
down units, general care or even at home.
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